Nutte van Belzen, MD | CC Diagnostics; Ronald Vos, BSc; Jolien de Waard, PhD; Ilinka Stanciu, MSc
Competition Sponsor: EIT Health
Awardee Year: 2025
CC Diagnostics aims to revolutionize cervical cancer screening. We have developed the Methica CC – a PCR-based test that detects damaged DNA that leads to cervical cancer. This test offers unmatched 97% cancer detection, easier access for the patients due to self-sampling compatibility, and a significant 6x reduction in time and cost per test for the diagnostic labs.